INTRODUCTION
The veterinary vaccines industry is a relatively small industry operating on a global scale. However, the movement of veterinary vaccines from production centres to markets throughout the world is subject to strict regulations, mainly intended to prevent the accidental importation of pathogenic organisms.
Any new scientific and political development which creates the possibility for removing trade barriers and facilitating the free movement of veterinary vaccines is clearly in the interest not only of the industry but also of its customers. The use of risk analysis techniques in determining the risks associated with the importation of veterinary vaccines, and the international harmonisation of technical requirements, could play an important role in the achievement of this goal.
Characteristics of the veterinary vaccine industry
Four characteristic features of the veterinary vaccine industry are described below (2) .
The first characteristic of the industry is that it is relatively small: it comprises only 18% of the total world market in animal health products, representing a turnover of approximately US$1.7 billion. This is approximately equal to the size of the market for human vaccines.
The second characteristic is that it is very fragmented. Many different vaccines are produced, intended for use in up to 15 species of animals and against many different pathogenic agents (160-200 strains). Consequently, the market potential for each individual vaccine is relatively small. This is in stark contrast to the market for human vaccines, which consists of only a very limited number of vaccines for a single species, namely humans.
The third characteristic is that, with the exception of vaccines for companion animals, the viability of products from the industry depends very much on the economy of the agricultural sector involved.
The fourth characteristic is that the licensing of veterinary vaccines is very strictly regulated throughout the world. These regulations require high standards of quality for starting materials and manufacturing conditions (with respect to both production facilities and production procedures). Regulations must guarantee that the final product meets the required high standards of consistent quality, safety and efficacy. These regulations increase the cost of manufacturing veterinary vaccines, which is already a technically-and logistically-complicated process.
These typical characteristics of the market, and the fact that the veterinary vaccine industry is already a global industry, explain why the industry is interested in harmonisation of technical requirements and free trade. The veterinary vaccine industry wants to be as flexible as possible in both technical and commercial aspects of its operations. The industry prefers to locate production centres where these are most advantageous, and wishes to be able to transport products to as many countries as possible for marketing. At present, the industry is unable to transport these products from the manufacturing sites to be marketed freely in all other parts of the world.
Regulation of trade in veterinary biologicals
The international movement of veterinary vaccines is very unbalanced. No veterinary vaccines are exported from the European Union (EU) to the United States of America (USA) or to Australia, and there is only limited export to Japan. In contrast, there is almost a free flow of veterinary vaccines into the EU from all parts of the world, notably from the USA. This is due to the current restrictions on the free movement of veterinary vaccines imposed by various governments. A more detailed examination of these restrictive measures shows that their purpose is not always the same.
The regulations on the importation of biological material into the USA are intended to prevent the accidental importation of disease agents which do not occur in the USA, notably foot and mouth disease (FMD) virus, classical swine fever (CSF)/hog cholera virus or, more recently, the agent of bovine spongiform encephalopathy (BSE). This type of trade restriction is commonly known as an 'exotic disease barrier'. The strictness of these regulations has made the importation of veterinary vaccines into the USA practically impossible.
The importation of veterinary vaccines into the EU is governed by Directive 81/851/EEC. This Directive is primarily intended to facilitate the free movement of veterinary medicinal products within the EU, which is only possible when all such products marketed within the EU meet the requirements for quality, safety and efficacy specified in Directive 81/852. Moreover, production must conform to 'good manufacturing practice' (GMP), as required by Directive 91/412 (5). The Directives do not directly prohibit the importation of veterinary vaccines, but they logically require that products imported into the EU meet the above standards, thus acting as a serious impediment to trade. To ensure the quality of imported products, Directive 81/851 requires each imported batch of product to undergo a full qualitative analysis in the importing country, in accordance with the requirements of the marketing authorisation. This makes importation costly and time-consuming, and affects the shelf-life of the imported batches.
It is important to note that the EU regulations do not prohibit the importation of veterinary vaccines. They require proof, however, that the imported vaccines meet the EU requirements, through re-testing of the final product. The EU regulations are not primarily intended to prevent the importation of exotic diseases. Over the last ten years, there has been a continuous flow of veterinary vaccines into the EU from the USA and other parts of the world. No outbreaks of exotic diseases which could be related to the importation of such products have been reported.
One EU Member State, the United Kingdom, has taken specific measures to prevent the importation of exotic diseases. These measures are based on the conviction that the importation of exotic diseases can be prevented by regular and careful inspection of production facilities and production procedures, and by quality control testing of each individual product for which a licence application was made in the United Kingdom. In fact, this constitutes a type of risk analysis procedure.
A new approach in preventing the importation of exotic disease has become necessary as a result of the Uruguay Round of the General Agreement on Tariffs and Trade (GATT; now World Trade Organisation: WTO). The specific WTO agreement on the application of sanitary and phytosanitary measures (SPS Agreement) seeks to ensure that trade restrictions ostensibly aimed at food safety or at the protection of plant or animal health should have a sound scientific basis. The USA has already anticipated this evolution and has recognised that the present 'zero-risk' policy can no longer be maintained. The United States Department of Agriculture, Animal and Plant Health Inspection Service (USDA/APHIS) has developed risk assessment techniques to provide an adequate scientific basis for any decisions on the importation of v eterinary vaccines.
Risk factors in the handling of veterinary biologicals
It is generally agreed that the aspects described below are the critical hazard points in the development and manufacture of veterinary biologicals.
Vaccine organism
The following features of the vaccine organism are critical for risk analysis:
-biological characteristics (e.g. danger for other species)
-genetic stability (e.g. reversion to virulence) -contamination with extraneous agents.
Materials used for the production of the vaccine (especially with respect to possible contamination by extraneous agents)
The nature of the materials used may be of vital importance to the risk analysis. Materials fall into one of the following categories:
-substrates (e.g. cells, eggs, animals) -other materials of biological origin (e.g. serum, trypsin).
Conditions of manufacture (to prevent cross-contamination during the production process)
Among these conditions, the following are considered the most crucial in relation to the risk of importation of foreign animal disease:
-use of contaminated materials in production -contamination during the production process.
Suitable, harmonised risk assessment techniques will have to be developed. A detailed examination of techniques applicable to veterinary biologicals has been provided by Osborne et al. (4) . Harmonised risk assessment techniques will help countries to agree on the definition of critical points, on the level of acceptable risk and on measures to control risk. These measures will include technical requirements for the control of finished products, and principles for the manufacture of vaccines.
Risk assessment and the harmonisation of technical standards
To provide harmonised technical requirements, the following tasks must be performed: a) identify the major risks associated with the global trade of veterinary biologicals b) determine at which point in the development and manufacture of veterinary biologicals these risks are likely to occur (as described above) c) identify controls, assays and data required to eliminate or minimise the identified risks d) use risk assessment tools to evaluate and, where necessary, to quantify the ability of the previously-identified controls, assays and data to eliminate or manage these risks.
Two main areas of risk are associated with the production and subsequent use of veterinary biologicals: contaminated product and manufacturing errors. This information can be used to identify the types of assays and controls needed to reduce these risks, and to determine how risk assessment can be used in harmonising the technical standards to ensure minimal risk to the agricultural community. A detailed examination of risk assessment techniques applicable to veterinary biologicals has been provided by Osborne et al. (4) .
When evaluating the risks associated with a particular contaminating agent and the possible ways to manage or control such risks, a number of factors must be considered. These factors, summarised in Table I , include the ease with which the contaminant can be cultured in vitro, the time from exposure to onset of clinical signs in vivo, the ease of transmission between vaccinated animals and non-vaccinated animals, and human and host pathogenicity. Obviously, a pathogen which is difficult or impossible to detect in vitro, and which induces a disease with delayed onset of clinical signs and has a potential human health risk, is of serious concern. The most recent example of such a potential contaminant is the BSE agent, although there has never been a documented case of BSE being caused by a contaminated conventional vaccine. Given that, for all practical purposes, contamination of a vaccine with BSE is almost impossible to detect in vitro or in vivo, risks associated with BSE contamination must be managed by control of raw materials.
Once a specific defect (in this case, a potential contaminating agent) is identified, the manufacturing process must be evaluated to determine where in the process this defect can occur (5). The production process for a typical veterinary biological is presented in Figure 1 . 
Flow diagram of the vaccine production process
For simplicity, the process has been divided into four steps, as follows: a) ingredients or starting materials (including raw materials of both biological and non-biological origin, viral and bacterial seeds and, where required, cell stocks) b) antigen production stage (including growth of the antigen and, where required, inactivation and downstream processing) c) bulk serial production (including assembly of the various finished vaccine components, addition of adjuvants, preservatives, etc.)
d) final batch finishing (including filling, labelling and desiccation, where required).
A flow chart such as this (Fig. 1) , with all the production details included, enables identification of the point in the process at which the greatest likelihood of specific production defects occurs.
For the introduction of a potential pathogen, the following elements can be used to control and quantify specific risks: a) history and source of any raw materials, with special consideration given to those of biological origin (e.g. sourcing of ingredients of bovine origin from countries documented as BSE-free) b) raw material processing steps (e.g. filtration, purification and inactivation) and the assays used to validate these procedures c) physical characteristics of the production process (including the ability of the pathogen to replicate in the production medium, additional inactivation steps and dilution considerations) d) assay procedures, both in-process and on the final product.
Steps a), b) and c) are based primarily on facts and data, and are therefore more easily harmonised.
Step d) varies according to country and regulatory environment. This variation complicates the establishment of global standards and increases cost to the industry in the form of duplicate test requirements. The goal of industry and regulators must be to work towards harmonised technical requirements. It is proposed that a programme to evaluate assays for technical equivalence (in terms of meeting the goal of the assay) be initiated by a joint industry/government working group. The following is a possible scenario for determining equivalence: a) identification of the purpose of the assay in relationship to the risk which the assay is intended to reduce or prevent b) identification of the ability of a particular assay to meet its intended goal, and generation of the required data c) incorporation, where possible, of risk assessment to quantify differences in assays as they pertain to the previously-identified purpose of the assay. Table II identifies base parameters to be considered in assays used to detect potential contaminating organisms, including assays for sterility, mycoplasma and extraneous agents.
By clearly defining the purpose of an assay, criteria similar to those presented in Table I may be used to generate data to help determine the suitability of the assay for a particular purpose. Assuming that various assays may be similar but not identical, differences can be quantified and the risks assessed. On the basis of the assessment, different assays may be recognised as equivalent. Failing this, a single test will have to be adopted (or developed) as a harmonised test. 
CONCLUSION
The veterinary vaccine industry -as represented world-wide by the Confédération Mondiale de l'Industrie de la Santé Animale (COMISA), in the USA by the Animal Health Institute/Veterinary Biologics Section (AHI/VBS) and in the EU by the European Federation of Animal Health (FEDES A) -is willing to participate actively in these discussions and in the scientific evaluation of the present test methods. As a first step, the EU and USA (specifically, the United States Department of Agriculture [USDA]) should agree to the free movement of veterinary vaccines, on the following conditions:
-that test methods on extraneous viruses be accepted as scientifically valid and equivalent -that GMP standards be accepted as equivalent, and inspection reports be mutually recognised -that results of risk assessment for products show a low or negligible risk -that the product meets the requirements of consistent quality, safety and efficacy.
The most important concern of the veterinary vaccine industry is whether there is sufficient political will and determination to achieve the goal of free trade in biologicals. This political will is essential. From the scientific point of view, it will no longer be possible to justify exotic disease barriers. Any risk assessment will indicate some degree of risk, however, although such risk may be negligible. This means that regulators must be prepared to accept some degree of risk. But this is nothing new and is already common practice in trade in animals and animal products (1, 3) .
Harmonised risk assessment procedures should be developed for a proper universal acceptance of these new rules. The OIE and WTO must play the leading role in this initiative. The SPS Agreement requires that risk assessments be transparent and that decisions be consistent. 
* * L'ÉVALUATION DES RISQUES APPLIQUÉE AUX PRODUITS BIOLOGIQUES

